U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAMENDMENT TRANSMITTAL
LETTER AND REQUEST FOR
EXTENSION OF TIME PURSUANT
TO 37 C.F.R. 1.136 (a)

Docket Number:

1662/60707

Application Number
10/621,623Filing Date
July 16, 2003Examiner
Laura Stockton,
Ph.D.Art Unit
1626Invention Title
NOVEL SYNTHESIS OF IRBESARTANInventors
DOLITZKY et al.Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450I hereby certify that this correspondence is being deposited
with the United States Postal Service with sufficient postage as
first class mail in an envelope addressed to: Mail Stop:
Amendment, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450 onDate: January 9, 2008

Signature:

Sir:

1. Transmitted herewith for filing is an Amendment and Attachments A and B in response to the Office Action mailed July 9, 2007 for the above-identified application.
2. Applicants hereby request a **three-month extension of time** to respond to the Office Action of July 9, 2007, which set a three-month period for response. The extended period for response now expires on January 9, 2008. Please charge the **\$1,050.00** extension fee and any additional fees to the deposit account of Kenyon & Kenyon LLP, deposit account number **11-0600**.
3. The filing fee has been calculated after entry of the accompanying Amendment as shown below:

01/14/2008 EAYALEW1 00000020 110600 10621623

01 FC:1253 1050.00 DA

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT NUMBER EXTRA	RATE (\$)	FEE (\$)
TOTAL CLAIMS	20	minus	20	0	50.00	0.00
INDEPENDENT CLAIMS	2	minus	3	0	200.00	0.00
MULTIPLE DEPENDENT CLAIM ADDED					360.00	0.00
					TOTAL	0.00
					SMALL ENTITY TOTAL	


4. No additional claims fee is due. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to the deposit account of **Kenyon & Kenyon LLP**, deposit account number **11-0600**:

- A. Any additional filing fees required under 37 C.F.R. § 1.16;
- B. Any additional patent application processing fees under 37 C.F.R. § 1.17;
- C. Any additional patent issue fees under 37 C.F.R. § 1.18;
- D. Any additional document supply fees under 37 C.F.R. § 1.19;
- E. Any additional post-patent processing fees under 37 C.F.R. § 1.20; or
- F. Any additional miscellaneous fees under 37 C.F.R. § 1.21.

5. A copy of this letter is enclosed.

Respectfully submitted,

Date: January 9, 2008


Gina R. Gencarelli
Reg. No. 59,729

KENYON & KENYON LLP
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646



Attorney Docket No. 1662/60707


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Dolitzky, et al.	Art Unit:	1626
Serial No.:	10/621,623	Examiner:	Laura Stockton, Ph.D.
Filed:	July 16, 2003		
For:	Novel Synthesis of Irbesartan		
Docket No.:	1662/60707		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with sufficient postage with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 1/9/08

Signature: 

Response to Office Action under 37 C.F.R. § 1.111

Dear Sir:

In response to the Office Action mailed on July 9, 2007, please enter the following amendments and consider the following remarks.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.